IHH Healthcare - CGS-CIMB Research 2021-12-01: Thriving Despite Waning COVID-19 Revenue

IHH Healthcare - Thriving Despite Waning COVID-19 Revenue

  • Yesterday’s post-results briefing gave us greater confidence in IHH Healthcare (SGX:Q0F)’s ability to cultivate the return of patient volumes to offset the COVID-19 revenue decline.
  • As the situation improves, more deals are on the cards to boost inorganic growth. The return of foreign tourists also serves as catalyst.
  • Reiterate ADD call on IHH Healthcare with a higher SOP target price of RM8.30. We increase our FY21-23F earnings per share forecast for IHH Healthcare by 5-11%, mainly factoring in higher revenue for all regions (especially India) and lower finance costs.

Above is the excerpt from research report by CGS-CIMB.
Clients of CGS-CIMB may access the full report in PDF @ https://www.itradecimb.com.sg/.

EING Kar Mei CFA CGS-CIMB Research | TAY Wee Kuang CGS-CIMB Research | https://www.cgs-cimb.com 2021-12-01
SGX Stock Analyst Report ADD MAINTAIN ADD 2.69 UP 2.360

Read also CGS-CIMB's most recent report:
2022-06-08 IHH Healthcare - Positive On International Medical University (IMU) Sale

Check out the most recent target prices at IHH Healthcare Target Prices. Listing of analyst research reports at IHH Healthcare Analyst Report.

Relevant links:
IHH Healthcare Share Price History,
IHH Healthcare Announcements,
IHH Healthcare Dividends & Corp Actions,
IHH Healthcare News Articles


SGX Stock / REIT Search